TrialThe New England journal of medicine2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Brian I Rini et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,879 papers cite itlatest 60 shown
this paperpooled ittrialcites it